Background: In this study, we aim to discuss the long-term clinical outcomes of intravascular ultrasound imaging-guided percutaneous intervention (IVUS-PCI) versus angiography-guided percutaneous c... Tweetable abstract A meta-analysis was conducted to compare intravascular ultrasound guidance/optical coherence tomography percutaneous coronary intervention with angiography percutaneous coronary ...

Background: Liver Cirrhosis is a growing cause of morbidity and mortality worldwide, but significant knowledge gaps remain regarding disparities in the place of patient death. This study aims to analyze the place of death trends for cirrhosis patients in the United States from 1999 to 2020, to direct preventive and palliative care measures.Methods: In this descriptive study, death certificates were examined using the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research (CDC WONDER) database, using ICD codes K70.3, K71.7, and K74. The variables studied were the year, sex, age, race, rural–urban, census regions, and state. Percentages of deaths in each location were trended over time for interpretation.Results: Between 1999 and 2020, a total of 1 090 420 deaths were attributed to cirrhosis. The majority of these fatalities occurred in inpatient medical facilities (48.75%), followed by the decedent's home (25.71%). Men consistently exhibited higher deaths in all settings, especially in medical facility—inpatient settings (31.39%), and the highest deaths were for the 55–64 age group. NH White population reported the highest mortality in all places of death, whereas the South led mortality records among census regions. The least deaths occurred in non‐core (non‐metro) areas, and state‐wise analysis revealed California to have the highest number of deaths (75 723), seconded by Texas (55 447).Conclusion: Mortality due to cirrhosis increased gradually from 1999 to 2019, with a steep rise observed in 2019–2020. Men, the White race, 55–65 years age bracket, and residents of rural and Southern census regions reported the highest number of deaths from cirrhosis.

Background: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with heart failure (HF) and type 2 diabetes. Their effect in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS), however, remains unclear. This study evaluated whether SGLT2 inhibitors reduce all‐cause mortality and HF hospitalisations after TAVR. Methods: A systematic search of PubMed, ScienceDirect, Cochrane (CENTRAL), Scopus and Embase was performed through April 2025 for studies comparing post‐TAVR outcomes between SGLT2 inhibitor users and non‐users. Outcomes of interest included a composite of all‐cause mortality or heart failure (HF) hospitalisation, along with the individual components of all‐cause mortality and HF hospitalisation. All outcomes were extracted at 1 year. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random‐effects model. Heterogeneity was quantified using I ² statistics. Analyses were conducted in R (version 4.4.2). Results: Three studies (1 RCT, 2 Observational) comprising 3187 patients met inclusion criteria. SGLT2 inhibitor use was associated with a reduced risk of the composite outcome (HR: 0.75; 95% CI: 0.65, 0.86; p < 0.01). Individually, therapy lowered all‐cause mortality (HR: 0.72; 95% CI: 0.53, 0.96; p = 0.03) and HF hospitalisations (HR: 0.74; 95% CI: 0.61, 0.90; p < 0.01). Conclusion: In patients with severe AS undergoing TAVR, SGLT2 inhibitors were associated with significant reductions in all‐cause mortality and HF hospitalisations. These findings suggest a promising role for SGLT2 inhibitors in improving post‐TAVR outcomes. However, given the limited data, larger randomised clinical trials are necessary to consolidate these findings. Trial Registration: CRD420251132729